Chemotherapy options for advanced ovarian cancer with high PARK2
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial compares two chemotherapy combinations before surgery for advanced ovarian cancer in people with a specific genetic marker (PARK2). It aims to find which treatment is more effective and safer for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have advanced ovarian, fallopian tube, or primary peritoneal cancer that is high-grade serous or endometrioid type.
- Your cancer is stage III or IV and cannot be fully removed with initial surgery, or you are not healthy enough for surgery.
- Your tumor and blood show high levels of the PARK2 gene.
- You have not had chemotherapy or other cancer treatments for this condition before.
- You are willing to provide tissue and blood samples and complete quality-of-life questionnaires.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This Phase 3 trial compares two different chemotherapy approaches for women with ovarian sex cord–stromal germ cell tumors. It aims to see which treatment works better and is safer for newly diagnosed stage IIA to IVB disease after surgery.
This Phase 3 trial tests two chemotherapy regimens (TC vs BEP) for women with malignant sex cord-stromal tumors of the ovary. It aims to see which treatment works better after you’ve had initial surgery to diagnose and/or remove tumor.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.